You are here
CareDx Profiles AlloSeq Suite of NGS Products at ASHI
Expands portfolio with three new kitted transplant products launching in 2019
Delivers new insights into the clinical Transplantome by incorporating HLA plus additional genes contributing to successful transplant outcomes
Enables global access for laboratories to assess organ health by measuring donor-derived cell-free DNA associated with allograft injury
BRISBANE, Calif. and BALTIMORE, Oct. 02, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA) today will profile the new AlloSeq suite of next generation sequencing based transplant laboratory products at a sponsored symposium at the 44th Annual Meeting of the American Society of Histocompatability and Immunogenetics (ASHI) in Baltimore, Maryland.
CareDx is driving clinical leadership in the transplant laboratory with the launch of three new AlloSeq kitted next generation sequencing (NGS) products in 2019. AlloSeq laboratory products leverage the strength of Illumina’s world-class NGS technology and CareDx’s deep understanding of transplantation research to enable personalized medicine solutions in the transplant clinic. These products will enable a wide range of new clinical insights into the Transplantome, the diverse network of biological interactions that affect solid organ and hematopoietic stem cell transplant patient outcomes.
The three new NGS laboratory products launching in 2019 are:
- AlloSeq HLA – The Next Generation of Transplant Matching with Full HLA Gene Coverage, Additional Gene Content and Streamlined Workflow
- AlloSeq cfDNA – Enabling Global Laboratories to Assess Organ Health by Measuring Donor-Derived Cell-Free DNA Associated with Allograft Injury
- AlloSeq BMT – Simplified Workflow and Automated Analysis for Chimerism Testing
“Following the exclusive Illumina NGS transplantation product distribution and development agreement, CareDx has focused on expanding the breadth of our product offering with the AlloSeq product lines. With our best in class NGS solutions, we will partner with transplant labs around the globe, improving transplant patient care,” said David Sayer, VP of Global Transplant Laboratory Solutions at CareDx.
“There is great excitement over the performance benefits of AlloSeq HLA, with complete gene coverage and additional panel content delivering outstanding matching information,” said Maria Bettinotti, Ph.D., D(ABHI), FACMG, Immunogenetics Laboratory Director at Johns Hopkins, “AlloSeq HLA will help us identify the best unrelated donor for future patients requiring a Bone Marrow Transplant and provide new insights into the biology of transplant matching.”
“CareDx’s AlloSeq cfDNA kits enable the surveillance of kidney transplant grafts in a quantitative manner, reducing the need for unnecessary invasive procedures and improving patient care. We are very excited to be an early access site for AlloSeq cfDNA and look forward to assessing the clinical implications and the benefits this kit will bring to our transplant patients,” said Natalia Diaz Burlinson, FRCPath Msc BSc(Hon) of the NHS Manchester Transplant Laboratory.
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure® for post-transplant surveillance and QTYPE®, TruSight® HLA, Olerup SSP® and Olerup SBT® for pre-transplant HLA testing.
For more information, please visit www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed by us with the SEC on March 22, 2018 and the periodic reports that we have subsequently filed with the SEC. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Chief Commercial Officer
Integrated Corporate Relations, Inc.